Skip to main content
NCBI home page
Food Science and Biotechnology logoLink to Food Science and Biotechnology
. 2016 Jun 30;25(3):899–904. doi: 10.1007/s10068-016-0147-y

Effects of long-term supplementation of policosanol on blood cholesterol/glucose levels and 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in a rat model fed high cholesterol diets

Jung-Yun Lee 2, Hwang-Yong Choi 2, Yu-Ri Kang 2, Hung-Bae Chang 1, Hyoung-Sik Chun 1, Mee-Sook Lee 2, Young-In Kwon 2,✉
PMCID: PMC6049138  PMID: 30263351

Abstract

Policosanol is a well-defined nutraceutical for the management of blood cholesterol levels. The present study examined (i) the effect of policosanol supplementation on blood cholesterol and glucose levels and (ii) changes in hepatic cholesterol biosynthesis using 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) activity in Wistar rats fed high cholesterol diets. The Wistar rats were assigned randomly to high-cholesterol diets (1.25% cholesterol) with or without policosanol (8.0 mg/kg body weight) for 6 weeks. Compared with the control group, dietary treatment with policosanol resulted in a significant decrease of blood cholesterol (p<0.01), blood glucose (p<0.01), triglyceride (p<0.001), and low density lipoprotein-cholesterol levels (p<0.01) and HMG-CoA reductase activity (p<0.001) in the liver. These results indicate that policosanol decreases blood cholesterol levels by suppressing cholesterol biosynthesis via decrease of HMG-CoA activity. Policosanol has the potential to be developed into an effective dietary strategy for both postprandial hyperglycemia and hypercholesterolemia.

Keywords: policosanol, low density lipoprotein-cholesterol, blood glucose, HMG-CoA reductase, hypercholesterolemia

References

  • 1.Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: A report from the American heart association. Circulation. 2014;131:e29–e322. doi: 10.1161/CIR.0000000000000152. [DOI] [PubMed] [Google Scholar]
  • 2.Lioyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121:568–613. doi: 10.1161/CIRCULATIONAHA.109.192703. [DOI] [PubMed] [Google Scholar]
  • 3.Grundy SM. HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia. New Engl. J. Med. 1988;319:24–32. doi: 10.1056/NEJM198807073190105. [DOI] [PubMed] [Google Scholar]
  • 4.Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 1992;33:1569–1582. [PubMed] [Google Scholar]
  • 5.Hernandez F, Illnait J, Mas R, Castano G, Fernandez L, Gonzalez M, Cordovi N, Fernandez JC. Effects of policosanol on serum lipids and lipoproteins in healthy volunteers. Curr. Ther. Res. 1992;51:568–573. [Google Scholar]
  • 6.Menedez R, Arruzarabala L, Mas R, Del Rio A, Amor A, Gonzalez RM, Carbajal D, Fraga V, Molina V, Illnait J. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Brit. J. Nutr. 1997;77:923–932. doi: 10.1079/BJN19970090. [DOI] [PubMed] [Google Scholar]
  • 7.Yanai H, Katsuyama H, Hamasaki H, Abe S, Tada N, Sako A. Effects of dietary fat intake on HDL metabolism. J. Clin. Med. Res. 2015;7:145–149. doi: 10.14740/jocmr2030w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Banerjee S, Ghoshal S, Porter TD. Activation of AMP-kinase by policosanol requires peroxisomal metabolism. Lipids. 2011;46:311–321. doi: 10.1007/s11745-011-3540-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Singh DK, Poster TD. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J. Pharmacol. Exp. Ther. 2006;318:1020–1026. doi: 10.1124/jpet.106.107144. [DOI] [PubMed] [Google Scholar]
  • 10.Beg ZH, Stonik JA, Brewer HB. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase: Regulation of enzymatic activity by phosphorylation and dephosphorylation. P. Natl. Acad. Sci. USA. 1978;75:3678–3682. doi: 10.1073/pnas.75.8.3678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Menendez R, Amor AM, Conzalez RM, Fraga V, Mas R. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol. Res. 1996;29:253–257. [PubMed] [Google Scholar]
  • 12.Oliaro-Bosso S, Calcio E, Mantegna S, Giraudo E, Meda C, Viola F, Cravotto G. Regulation of HMG-CoA reductase activity by policosanol and octacosadienol, a new synthetic analogue of octacosanol. Lipids. 2009;44:907–916. doi: 10.1007/s11745-009-3338-y. [DOI] [PubMed] [Google Scholar]
  • 13.Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–1646. doi: 10.1126/science.1120781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 2007;100:328–341. doi: 10.1161/01.RES.0000256090.42690.05. [DOI] [PubMed] [Google Scholar]
  • 15.Banerjee S, Ghoshal S, Porter DT. Phosphorylation of hepatic AMP-activated protein kinase and liver kinase B1 is increased after a single oral dose of green tea extract to mice. Nutr. Res. 2012;32:985–990. doi: 10.1016/j.nutres.2012.10.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Xie Z, Dong R, Scholz D, Neumann M, Zou H. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation. 2008;117:952–962. doi: 10.1161/CIRCULATIONAHA.107.744490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Zatara G, Bar-Tana J, Kalderon B, Suter M, Morad E, Samovski D, Neumann D, Hertz R. AMPK activation by long chain fatty acyl analogs. Biochem. Pharmacol. 2008;76:1263–1275. doi: 10.1016/j.bcp.2008.08.028. [DOI] [PubMed] [Google Scholar]
  • 18.Renu A, Shrewsbury AM. 3-Hydroxy-3-methylglutaryl Coenzyme A reductase from rat liver. J. Biol. Chem. 1976;251:3815–3822. [PubMed] [Google Scholar]
  • 19.Rodríguez-Echenique C, Mesa R, Más R, Noa M, Menéndez R, González RM, Amor AM, Fraga V, Sotolongo V, Laguna A. Effect of policosanol chronically administered in male monkeys (Macaca arctoides) Food Chem. Toxicol. 1994;32:565–575. doi: 10.1016/0278-6915(94)90115-5. [DOI] [PubMed] [Google Scholar]
  • 20.Castano G, Fernadez L, Mas R, Iiinait J, Mesa M, Fernandez JC. Comparison of the effects of Policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clin. Drug Invest. 2003;23:639–650. doi: 10.2165/00044011-200323100-00003. [DOI] [PubMed] [Google Scholar]
  • 21.Castaño G, Mas R, Fernández L, Illnait J, Gámez R, Alvarez E. Effects of Policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: A 6-month double-blind study. Int. J. Clin. Pharm. Res. 2001;21:43–57. [PubMed] [Google Scholar]
  • 22.Gouni-Berthold I, Berthold HK. Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am. Heart J. 2002;143:356–365. doi: 10.1067/mhj.2002.119997. [DOI] [PubMed] [Google Scholar]
  • 23.Heiner KB, Susanne U, Ralf D, Michael BD, Ioanna GB. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia. JAMA-J. Am. Med. Assoc. 2006;295:2262–2269. doi: 10.1001/jama.295.19.2262. [DOI] [PubMed] [Google Scholar]
  • 24.Pons P, Rodriguez M, Robaina C, Illnait J, Mas R, Fernandez L, Fernandez JC. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int. J. Clin. Pharm. Res. 1994;14:27–33. [PubMed] [Google Scholar]
  • 25.Chen JT, Wesley R, Shamburek RD, Pucino FC. GMeta-analysis of natural therapies for hyperlipidemia: Plant sterols and stanols versus policosanol. Pharmacotherapy. 2005;25:171–183. doi: 10.1592/phco.25.2.171.56942. [DOI] [PubMed] [Google Scholar]
  • 26.Barrat E, Zaïr Y, Sirvent P, Chauveau P, Maudet C, Housez B, Derbord E, Lescuyer JF, Bard JM, Cazaubiel M, Peltier SL. Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: A randomised, double-blind, placebo-controlled study. Eur. J. Nutr. 2013;52:1843–1852. doi: 10.1007/s00394-012-0486-2. [DOI] [PubMed] [Google Scholar]
  • 27.Ogier N, Amiot MJ, Georgé S, Maillot M, Mallmann C, Maraninchi M, Morange S, Lescuyer JF, Peltier SL, Cardinault N. LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia. Eur. J. Nutr. 2013;52:547–557. doi: 10.1007/s00394-012-0357-x. [DOI] [PubMed] [Google Scholar]
  • 28.Li Q, Thomson AB, Clandinin MT. Cholesterol ester and free fatty acids are modulated by policosanol in CaCo-2 intestinal cell. J. Am. Coll. Nutr. 2011;30:201–209. doi: 10.1080/07315724.2011.10719961. [DOI] [PubMed] [Google Scholar]
  • 29.Chi HN, Ka YL, Yu H, Zhen YC. Policosanol has no antioxidant activity in human low-density lipoprotein but increase excretion of bile acids in hamsters. J. Agr. Food Chem. 2005;53:6289–6293. doi: 10.1021/jf051269a. [DOI] [PubMed] [Google Scholar]

Articles from Food Science and Biotechnology are provided here courtesy of Springer

RESOURCES